Search research articles
Contact Us
Filters
Showing results (31-40 of 57) with videos related to
Page
of 6
Sort By:
Cell Reports
|
April 24, 2024
Batf3<sup>+</sup> DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy
Andrea Ziblat, Brendan L Horton, Emily F Higgs, et al.
Scientific Reports
|
May 12, 2021
Multi-step screening of neoantigens' HLA- and TCR-interfaces improves prediction of survival
Guilhem Richard, Anne S De Groot, Gary D Steinberg, et al.
Breast Cancer Research and Treatment
|
November 23, 2024
High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltration
Margarite D Matossian, Christine Shiang, Deniz Nesli Dolcen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 23, 2025
Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas
Jason J Luke, Randy F Sweis, J Randolph Hecht, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 1, 2025
A Prospective Study of Stereotactic Body Radiation Therapy in Oligometastatic Renal Cell Carcinoma
Rohan R Katipally, Greeshma Rajeev-Kumar, Abhishek A Solanki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2026
Lipid Nanoparticle-encapsulated mRNA-2752 Encoding Human OX40L, IL-23, and IL-36γ Plus Durvalumab Induces an Immunostimulatory Effect Within the Tumor Microenvironment in Patients with Advanced Solid Tumors
Randy F Sweis, Georgina V Long, Adil Daud, et al.
Clinical and Translational Radiation Oncology
|
November 12, 2024
Primary site stereotactic ablative body radiotherapy in localized, recurrent, and metastatic renal cell carcinoma
Daniel Huang, Connor Lynch, Lucas M Serra, et al.
JAMA Oncology
|
September 19, 2024
Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With <i>FGFR</i> RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical Trial
Randy F Sweis, Pablo Gajate, Rafael Morales-Barrera, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2021
Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
Funda Meric-Bernstam, Randy F Sweis, F Stephen Hodi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 22, 2024
A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer
Randy F Sweis, Gurkamal S Chatta, Rohit K Jain, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 57) with videos related to
Sort By:
Page
of 6
Cell Reports
|
April 24, 2024
Batf3<sup>+</sup> DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy
Andrea Ziblat, Brendan L Horton, Emily F Higgs, et al.
Scientific Reports
|
May 12, 2021
Multi-step screening of neoantigens' HLA- and TCR-interfaces improves prediction of survival
Guilhem Richard, Anne S De Groot, Gary D Steinberg, et al.
Breast Cancer Research and Treatment
|
November 23, 2024
High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltration
Margarite D Matossian, Christine Shiang, Deniz Nesli Dolcen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 23, 2025
Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas
Jason J Luke, Randy F Sweis, J Randolph Hecht, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 1, 2025
A Prospective Study of Stereotactic Body Radiation Therapy in Oligometastatic Renal Cell Carcinoma
Rohan R Katipally, Greeshma Rajeev-Kumar, Abhishek A Solanki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2026
Lipid Nanoparticle-encapsulated mRNA-2752 Encoding Human OX40L, IL-23, and IL-36γ Plus Durvalumab Induces an Immunostimulatory Effect Within the Tumor Microenvironment in Patients with Advanced Solid Tumors
Randy F Sweis, Georgina V Long, Adil Daud, et al.
Clinical and Translational Radiation Oncology
|
November 12, 2024
Primary site stereotactic ablative body radiotherapy in localized, recurrent, and metastatic renal cell carcinoma
Daniel Huang, Connor Lynch, Lucas M Serra, et al.
JAMA Oncology
|
September 19, 2024
Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With <i>FGFR</i> RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical Trial
Randy F Sweis, Pablo Gajate, Rafael Morales-Barrera, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2021
Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
Funda Meric-Bernstam, Randy F Sweis, F Stephen Hodi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 22, 2024
A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer
Randy F Sweis, Gurkamal S Chatta, Rohit K Jain, et al.
Page
of 6